Brain Alterations Based on Multiplex MR Imaging in Nasopharyngeal Carcinoma Patients After Treatment, and Their Correlation With Clinical Cognitive Scores.

NCT07011329 · tracked via the Priya Life Science China tracker

Sponsor

Hubei Cancer Hospital

Phase

Observational

Started

2023-04-01

Last updated

2025-06-11

Condition(s) studied

Nasopharyngeal Carcinoma (NPC)

Investigational drug(s) / intervention(s)

Changes in the brain MTP parameters after radiotherapy

Changes in the brain MTP parameters after radiotherapy: Our study explores the changes in brain MTP parameters and their correlation with clinical cognitive scores before and after chemotherapy and/or radiotherapy in patients with NPC. We investigates MRI-derived multiparametric imaging biomarkers (MTP) as predictive biomarkers for chemotherapy/radiotherapy-induced cognitive decline in nasopharyngeal carcinoma, aiming to optimize neurotoxicity risk stratification and guide personalized neuroprotective interventions in precision oncology.

Study summary

The objective of this study is to examine the potential impact of the treatment before, during, and/or after radiotherapy on the brain in patients with nasopharyngeal carcinoma (NPC) using Multiplex (MTP) MR imaging sequence, which generate multiple contrasts with one-time scan. We aimed to investigate the altered MTP parameters and their correlation with clinical cognitive scores before and after the treatment.

Eligibility

Sex

ALL

Min age

30 Years

Max age

80 Years

Healthy volunteers

Accepted

Inclusion Criteria: * pathological evidence of NPC (stages III-IV at diagnosis according to the 8th edition of the UICC/AJCC staging system for NPC) * right-handed * prepared to receive treatments * prepared to receive the Montreal Cognitive Assessment (MoCA) Exclusion Criteria: * brain invasion * brain tumor or atrophy, neural-associated diseases, a history of brain surgery * any current medications that may affect cognitive function * inability to attend MRI scanning

Primary outcome measure(s)

volume — 3 months
the brain volume changes after treatment in NPC patients

Trial sites (1)

Facility	City	Region	Status
Department of Radiology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology	Wuhan	Hubei

More Hubei Cancer Hospital trials in China

Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy Recruiting

DIEP Flap Breast Reconstruction: Perioperative Biomarkers and Outcomes Recruiting

SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast Cancer Recruiting

Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC Starting soon

A Study on Combined Low-pass Whole-genome and Methylome Testing of Bloody Nipple Discharge Specimens for Benign-Malignant Differentiation. Recruiting

Other trials for the same condition

Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Active, not recruiting

Comparison of Multi-omics Models for Early Nasopharyngeal Carcinoma Screening: cfDNA Methylation, EBV DNA, and Serological Double-antibodies Detection Active, not recruiting

Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma Recruiting

Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study Starting soon

Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07011329 on ClinicalTrials.gov ↗ ← All trials in China